[go: up one dir, main page]

CA2491665A1 - Formulation de comprime pour liberation soutenue de principe actif - Google Patents

Formulation de comprime pour liberation soutenue de principe actif Download PDF

Info

Publication number
CA2491665A1
CA2491665A1 CA002491665A CA2491665A CA2491665A1 CA 2491665 A1 CA2491665 A1 CA 2491665A1 CA 002491665 A CA002491665 A CA 002491665A CA 2491665 A CA2491665 A CA 2491665A CA 2491665 A1 CA2491665 A1 CA 2491665A1
Authority
CA
Canada
Prior art keywords
matrix
tablet formulation
sustained release
active substances
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002491665A
Other languages
English (en)
Inventor
Louis Cartilier
Mihaela Ungur
Chafic Chabli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Universite de Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Montreal filed Critical Universite de Montreal
Priority to CA002491665A priority Critical patent/CA2491665A1/fr
Priority to JP2007547121A priority patent/JP2008525322A/ja
Priority to PCT/CA2005/001934 priority patent/WO2006066399A1/fr
Priority to KR1020077016954A priority patent/KR20070094009A/ko
Priority to EP05820905A priority patent/EP1833468A1/fr
Priority to US11/793,994 priority patent/US20090011014A1/en
Priority to CNA2005800444815A priority patent/CN101087595A/zh
Priority to BRPI0520610-3A priority patent/BRPI0520610A2/pt
Priority to AU2005318827A priority patent/AU2005318827A1/en
Priority to CA002591806A priority patent/CA2591806A1/fr
Publication of CA2491665A1 publication Critical patent/CA2491665A1/fr
Priority to IL184067A priority patent/IL184067A0/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

~,~r'~;WC:un nü?i:D~:. ,~llï~;-0 ~W :îl;iW :~:
F:_~ures:
P;1~?eS:
V
Unscannable items reoe:~red with this application (Reçuest oh'rinal documents in Fiïe Prep. S~:ction on the IOth Floorj D~.c~,~menzs -e-~as aven ce~e demande ne pou~JanL ~:ro oai:~;~és -r , . T ~ . ,. ; ~ a ~ -= r~ , r ~~ommrnder :es ~ioc:.ame:. ~PV_na~:~ , an.. .a ~eo Lon de pré;_~ar~zLon ~e~
~. o~..~~... au nième ~«~Te;

Claims

REVENDICATION
1. Formulation de comprimé matriciel comprenant un mélange d'une matrice d'au moins un polymère, d'au moins une substance ionique soluble et d'au moins un principe actif; ladite formulation étant caractérisée en ce que:
- la matrice d'au moins un polymère est à base d'amidon à haute teneur en amylose;
- l'au moins un polymère est associé à l'au moins une substance ionique soluble; et - le principe actif est inclus à l'intérieur de la matrice et est libéré de façon soutenue;
de sorte que le comprimé matriciel demeure intègre dans des conditions données.
CA002491665A 2004-12-24 2004-12-24 Formulation de comprime pour liberation soutenue de principe actif Abandoned CA2491665A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA002491665A CA2491665A1 (fr) 2004-12-24 2004-12-24 Formulation de comprime pour liberation soutenue de principe actif
US11/793,994 US20090011014A1 (en) 2004-12-24 2005-12-20 Tablet Formulation for Sustained Drug-Release
PCT/CA2005/001934 WO2006066399A1 (fr) 2004-12-24 2005-12-20 Preparation sous forme de comprime pour liberation medicamenteuse prolongee
KR1020077016954A KR20070094009A (ko) 2004-12-24 2005-12-20 약물의 지속방출을 위한 정제 제제
EP05820905A EP1833468A1 (fr) 2004-12-24 2005-12-20 Preparation sous forme de comprime pour liberation medicamenteuse prolongee
JP2007547121A JP2008525322A (ja) 2004-12-24 2005-12-20 薬物の徐放のための錠剤
CNA2005800444815A CN101087595A (zh) 2004-12-24 2005-12-20 用于缓释药物的片剂
BRPI0520610-3A BRPI0520610A2 (pt) 2004-12-24 2005-12-20 formulação de comprimido de medicamento para alìvio de dor
AU2005318827A AU2005318827A1 (en) 2004-12-24 2005-12-20 Tablet formulation for sustained drug-release
CA002591806A CA2591806A1 (fr) 2004-12-24 2005-12-20 Preparation sous forme de comprime pour liberation medicamenteuse prolongee
IL184067A IL184067A0 (en) 2004-12-24 2007-06-19 Tablet formulation for sustained drug-release

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002491665A CA2491665A1 (fr) 2004-12-24 2004-12-24 Formulation de comprime pour liberation soutenue de principe actif

Publications (1)

Publication Number Publication Date
CA2491665A1 true CA2491665A1 (fr) 2006-06-24

Family

ID=36601318

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002491665A Abandoned CA2491665A1 (fr) 2004-12-24 2004-12-24 Formulation de comprime pour liberation soutenue de principe actif

Country Status (10)

Country Link
US (1) US20090011014A1 (fr)
EP (1) EP1833468A1 (fr)
JP (1) JP2008525322A (fr)
KR (1) KR20070094009A (fr)
CN (1) CN101087595A (fr)
AU (1) AU2005318827A1 (fr)
BR (1) BRPI0520610A2 (fr)
CA (1) CA2491665A1 (fr)
IL (1) IL184067A0 (fr)
WO (1) WO2006066399A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1935411A1 (fr) 2006-12-15 2008-06-25 Campina Nederland Holding B.V. Excipient à libération prolongée et son utilisation
EP2101743B1 (fr) * 2006-12-15 2010-06-23 Campina Nederland Holding B.V. Excipient à libération modifiée et son utilisation
CA2590821A1 (fr) * 2007-06-07 2008-12-07 Universite De Montreal Excipient d'amidon carboxymethyle sodique a forte teneur en amylose a liberation prolongee et processus de preparation connexe
EP2415460A1 (fr) * 2010-08-03 2012-02-08 ratiopharm GmbH Formulations pour l'administration orale de prégabaline
WO2012116434A1 (fr) * 2011-03-01 2012-09-07 4413261 Canada Inc. (Spencer Canada) Système monolithique à deux vitesses pour la libération contrôlée de médicaments
CN103305748A (zh) 2012-03-15 2013-09-18 宝山钢铁股份有限公司 一种无取向电工钢板及其制造方法
GB201622024D0 (en) 2016-11-14 2017-02-08 Inventage Lab Inc Apparatus and method for large scale production of monodisperse, microsheric and biodegradable polymer-based drug delivery
KR20200013170A (ko) 2018-07-20 2020-02-06 주식회사 코아팜바이오 약물 방출 제어 구조를 포함하는 정제 및 3d 프린트 기술을 이용한 정제 제조방법
CN111198246B (zh) * 2018-11-19 2022-07-15 上海梅山钢铁股份有限公司 一种烧结脱硫脱硝灰中碳酸钙含量的检测方法
CN110200947A (zh) * 2019-06-27 2019-09-06 深圳市泛谷药业股份有限公司 一种安非他酮肠溶缓释微丸胶囊及其制备方法
CN115317459B (zh) * 2022-09-05 2023-10-31 安徽金太阳生化药业有限公司 一种氯霉素片的制备工艺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3034911A (en) * 1959-03-25 1962-05-15 Nat Starch Chem Corp Tablet disintegrants
US3490742A (en) * 1966-01-14 1970-01-20 Staley Mfg Co A E Compressed tablets
US3622677A (en) * 1969-07-07 1971-11-23 Staley Mfg Co A E Compressed tablets containing compacted starch as binder-disintegrant ingredient
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
US4369308A (en) * 1981-07-24 1983-01-18 National Starch And Chemical Corporation Low swelling starches as tablet disintegrants
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
GB8812490D0 (en) * 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5468286A (en) * 1989-10-25 1995-11-21 National Starch And Chemical Investment Holding Corporation Enzymatically debranched starches as tablet excipients
ATE112491T1 (de) * 1990-09-13 1994-10-15 Akzo Nobel Nv Stabilisierte feste chemische zusammensetzungen.
CA2041774C (fr) * 1990-11-27 1994-04-19 Mircea A. Mateescu Utilisation d'amylose reticulee en tant que matrice pour la liberation lente de composes biologiquement actifs
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
JP4072597B2 (ja) * 1994-12-27 2008-04-09 ナムローゼ・フェンノートシャップ・オルガノン 持続性製剤
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
DE19640062B4 (de) * 1996-09-28 2006-04-27 Lts Lohmann Therapie-Systeme Ag Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff
US5879707A (en) * 1996-10-30 1999-03-09 Universite De Montreal Substituted amylose as a matrix for sustained drug release
US5807575A (en) * 1997-02-14 1998-09-15 Rougier Inc. Manufacture of cross-linked amylose useful as a excipient for control release of active compounds
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
IT1318597B1 (it) * 2000-06-23 2003-08-27 A C R Applied Coating Res S A Uso di un amido ad alto contenuto di amilosio acetilato epregelatinizzato.
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
RU2333745C2 (ru) * 2002-10-25 2008-09-20 Лабофарм Инк. Композиции с контролируемым высвобождением

Also Published As

Publication number Publication date
IL184067A0 (en) 2007-10-31
CN101087595A (zh) 2007-12-12
AU2005318827A1 (en) 2006-06-29
KR20070094009A (ko) 2007-09-19
JP2008525322A (ja) 2008-07-17
WO2006066399A1 (fr) 2006-06-29
EP1833468A1 (fr) 2007-09-19
BRPI0520610A2 (pt) 2009-10-06
US20090011014A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
CA2491665A1 (fr) Formulation de comprime pour liberation soutenue de principe actif
Nair et al. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus
Takane et al. Polymorphism in human organic cation transporters and metformin action
Navarro et al. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration
Franse et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP)
Krepinsky et al. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease
Asderakis et al. Association of polymorphisms in the human interferon-γ and interleukin-10 gene with acute and chronic kidney transplant outcome: the cytokine effect on transplantation
Haas et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration
Shu et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics
Gramatté et al. Intestinal secretion of intravenous talinolol is inhibited by luminal R‐verapamil
Haynes et al. Effects of lowering LDL cholesterol on progression of kidney disease
Singh Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy
Plosker et al. Troglitazone: a review of its use in the management of type 2 diabetes mellitus
MA33064B1 (fr) Systemes à base de conjugués pour administration contrôlée de médicaments
Kopf et al. Cytochrome P4501A1 is required for vascular dysfunction and hypertension induced by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin
Kagaya et al. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients
Filippatos et al. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis
Kim et al. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients
TNSN08152A1 (fr) Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation
Lê et al. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial
Luo et al. Epidermal, sebaceous, and melanocytic nevoid proliferations are spectrums of mosaic RASopathies
Chen et al. Is vitamin D supplementation an effective treatment for hypertension?
Rattanacheeworn et al. SLCO1B1 and ABCG2 gene polymorphisms in a Thai population
Piechowski-Jozwiak et al. Secondary prevention of stroke with antiplatelet agents in patients with diabetes mellitus
Verma The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction

Legal Events

Date Code Title Description
FZDE Discontinued